FUNCTIONAL ACTIVITY OF BLOOD MICROPARTICLES IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PATIENTS

Introduction. Classical Ph-negative myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are often associated with thrombotic events. Managing and preventing these complications are crucial in patient care. Blood microparticles play a role in promoting clot formation and contribute to thrombotic complications in these conditions. Objectives. This study aimed to assess the procoagulant activity of microparticles in patients with Ph-negative myeloproliferative neoplasms. Methods. A total of 141 patients were included in this study, with 57 patients receiving antiplatelet therapy, 45 undergoing cytoreductive treatment, and 14 being treated with ruxolitinib. The calibrated automated thrombogram assay was utilized to assess microparticles' thrombin potential using the "PRP-Reagent" and "MP-Reagent." Statistical analysis was performed using Statistica 12.0, and significance between groups was determined at p<0.05 using the Mann-Whitney test. Results. The procoagulant activity of microparticles in patients with Ph-negative myeloproliferative neoplasms exhibited a wide range of values, from normal to significantly elevated parameters. Approximately 50% of patients treated with antiplatelets displayed increased microparticle thrombin potential. Patients with polycythemia vera and primary myelofibrosis undergoing cytoreductive therapy showed a reduction in the frequency of elevated thrombin potential values. Treatment with ruxolitinib in primary myelofibrosis patients led to a decrease in both the frequency and thrombin potential parameters using the "PRP-Reagent." Evaluation of microparticles' procoagulant activity with the "MP-Reagent" demonstrated an increase in values among patients with primary myelofibrosis receiving targeted therapy. Conclusion. Evaluating microparticle thrombin potential can serve as a valuable tool for assessing thrombotic risk in patients with Ph-negative myeloproliferative neoplasms.